Risk factors for antituberculous chemotherapy-induced hepatotoxicity in Japanese pediatric patients

被引:41
作者
Ohkawa, K
Hashiguchi, M
Ohno, K
Kiuchi, C
Takahashi, S
Kondo, S
Echizen, H
Ogata, H
机构
[1] Meiji Pharmaceut Univ, Dept Med Use Anal & Clin Res, Postgrad Sch Clin Pharm, Tokyo 2048588, Japan
[2] Meiji Pharmaceut Univ, Dept Pharmacotherapy, Tokyo 2048588, Japan
[3] Meiji Pharmaceut Univ, Dept Biopharmaceut, Tokyo 2048588, Japan
[4] Tokyo Metropolitan Kiyose Childrens Hosp, Dept Hosp Pharm, Tokyo, Japan
[5] Tokyo Metropolitan Kiyose Childrens Hosp, Dept Internal Med, Tokyo, Japan
关键词
D O I
10.1067/mcp.2002.126175
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: Our objective was to clarify risk factors associated with the development of severe hepatotoxicity during antituberculosis chemotherapy in Japanese children. Methods: In a retrospective analysis in a 350-bed referral children's hospital in a metropolitan area, the medical charts of all pediatric patients who received antituberculosis chemotherapy between January 1995 and November 1999 were surveyed. Univariate and multivariate analyses were performed to find any demographic parameters (ie, sex, age, height, and body weight), clinical characteristics (ie, nutritional or developmental status, co-infection with hepatitis viruses [B or C] or human immunodeficiency virus, presence of extrapulmonary tuberculosis, or medical history of liver disease), or individual antituberculosis agents used that would be associated with the likelihood of development of severe hepatotoxicity during antitubercutous chemotherapy. Severe hepatotoxicity (defined as an elevation of ALT and AST levels that were greater than 5 times the respective reference values) was attributed to the chemotherapy when it developed in children with normal pretreatment values for these parameters and no other potential causes were identified. Those who had abnormal ALT or AST values before treatment were excluded from analysis. Results: Among the 117 patients surveyed (58 males and 59 females; age range, 0 to 16 years), 18 were excluded from the analysis because of abnormal baseline ALT and AST values. Severe hepatotoxicity developed in 8 of the 99 eligible children, and all 8 of those children were younger than 5 years old. The univariate analysis revealed that the children in whom hepatotoxicity developed were significantly (P < .05) younger, were predominantly male, had extrapulmonary tuberculosis, and were given pyrazinamide more often than those who had no hepatotoxicity. However, the multivariate logistic regression analysis revealed that only age and the administration of pyrazinamide would have a significant contribution (P < .05) to the development of severe hepatotoxicity, with odds ratios of 143 (95% confidence interval, 4.2 to 4934.9) and 0.60 (95% confidence interval, 0.39 to 0.90), respectively: the estimated probability of development of hepatotoxicity in atypical pediatric patient at 1, 5, and 10 years receiving pyrazinamide with rifampin (INN, rifampicin) and isoniazid would be 0.95, 0.72, and 0.16, respectively. Conclusions: This study indicated that intensive monitoring of hepatotoxicity should be performed for younger children (<5 years) receiving pyrazinamide for antituberculosis chemotherapy.
引用
收藏
页码:220 / 226
页数:7
相关论文
共 22 条
[1]  
Aziz S, 1990, J Pak Med Assoc, V40, P290
[2]  
BAREGGI SR, 1987, ARZNEIMITTEL-FORSCH, V37-2, P849
[3]  
BLACK M, 1975, GASTROENTEROLOGY, V69, P289
[4]   Valproic acid hepatic fatalities .3. US experience since 1986 [J].
Bryant, AE ;
Dreifuss, FE .
NEUROLOGY, 1996, 46 (02) :465-469
[5]   RISK-FACTORS FOR ISONIAZID (INH)-INDUCED LIVER DYSFUNCTION [J].
DICKINSON, DS ;
BAILEY, WC ;
HIRSCHOWITZ, BI ;
SOONG, SJ ;
EIDUS, L ;
HODGKIN, MM .
JOURNAL OF CLINICAL GASTROENTEROLOGY, 1981, 3 (03) :271-279
[6]   Liver injury during antituberculosis treatment: An 11-year study [J].
Dossing, M ;
Wilcke, JTR ;
Askgaard, DS ;
Nybo, B .
TUBERCLE AND LUNG DISEASE, 1996, 77 (04) :335-340
[7]   VALPROIC ACID HEPATIC FATALITIES - A RETROSPECTIVE REVIEW [J].
DREIFUSS, FE ;
SANTILLI, N ;
LANGER, DH ;
SWEENEY, KP ;
MOLINE, KA ;
MENANDER, KB .
NEUROLOGY, 1987, 37 (03) :379-385
[8]   N-ACETYLATION POLYMORPHISM OF DAPSONE IN A JAPANESE POPULATION [J].
HORAI, Y ;
ISHIZAKI, T .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1988, 25 (04) :487-494
[9]   A prospective clinical study of isoniazid-rifampicin-pyrazinamide-induced liver injury in an area endemic for hepatitis B [J].
Hwang, SJ ;
Wu, JC ;
Lee, CN ;
Yen, FS ;
Lu, CL ;
Lin, TP ;
Lee, SD .
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 1997, 12 (01) :87-91
[10]  
KONIG SA, 1994, EPILEPSIA, V35, P1005